接受化疗联合或不联合放疗治疗的霍奇金淋巴瘤的极晚期复发：线性模式及独特的预后因素 - Suppr | 超能文献

Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.

作者信息

Vassilakopoulos Theodoros P, Kravvariti Evrydiki, Panitsas Fotios, Angelopoulou Maria K, Liaskas Athanasios, Kontopidou Flora N, Yiakoumis Xanthoula, Variami Eleni, Dimopoulou Maria N, Siakantaris Marina P, Asimakopoulos John V, Arapaki Maria, Dimou Maria, Diamantopoulos Panagiotis, Sachanas Sotirios, Chatzidimitriou Chrysovalantou, Belia Marina, Konstantinou Elianna, Boutsikas George, Petevi Kyriaki, Kanellopoulos Alexandros, Kokoris Styliani, Kyrtsonis Marie-Christine, Viniou Nora-Athina, Lakiotaki Eleftheria, Tsourouflis Gerasimos, Korkolopoulou Penelope, Konstantopoulos Kostas, Panayiotidis Panayiotis, Pangalis Gerassimos A

机构信息

Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

First Department of Propaedeutic Internal Medicine, Joint Rheumatology Academic Program, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

出版信息

Blood Cancer J. 2022 Jul 5;12(7):102. doi: 10.1038/s41408-022-00674-w.

DOI:10.1038/s41408-022-00674-w

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9256621/

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.

Blood Cancer J. 2022 Jul 5;12(7):102. doi: 10.1038/s41408-022-00674-w.

2

Treatment of lymphocyte-predominant Hodgkin lymphoma.

Ann Oncol. 2008 Jun;19 Suppl 4:iv45-6. doi: 10.1093/annonc/mdn194.

3

[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):630-4.

4

Central nervous system relapse in Hodgkin lymphoma: Successful treatment without radiotherapy.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26277. Epub 2016 Oct 12.

5

Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.

JAMA Oncol. 2018 Aug 1;4(8):1120-1121. doi: 10.1001/jamaoncol.2018.1767.

6

Combination chemoradiotherapy in early Hodgkin lymphoma.

Hematol Oncol Clin North Am. 2014 Feb;28(1):33-47. doi: 10.1016/j.hoc.2013.10.010.

7

Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.

J Cancer Res Clin Oncol. 2018 May;144(5):935-943. doi: 10.1007/s00432-018-2613-9. Epub 2018 Feb 21.

8

Hodgkin lymphoma.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. doi: 10.6004/jnccn.2011.0086.

9

Unusual presentation of classic Hodgkin lymphoma.

Blood. 2019 Jan 31;133(5):502. doi: 10.1182/blood-2018-10-878058.

10

Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?

Curr Hematol Malig Rep. 2014 Sep;9(3):217-21. doi: 10.1007/s11899-014-0214-5.

引用本文的文献

1

Treatment Classification by Intent in Oncology-The Need for Meaningful Definitions: Curative, Palliative and Potentially Life-Prolonging.

J Pers Med. 2024 Aug 31;14(9):932. doi: 10.3390/jpm14090932.

2

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study.

Hemasphere. 2024 Jul 3;8(7):e68. doi: 10.1002/hem3.68. eCollection 2024 Jul.

3

Harnessing multi-source data for individualized care in Hodgkin Lymphoma.

Blood Rev. 2024 May;65:101170. doi: 10.1016/j.blre.2024.101170. Epub 2024 Jan 14.

4

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.

Int J Mol Sci. 2023 Aug 24;24(17):13187. doi: 10.3390/ijms241713187.

5

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.

Blood Adv. 2023 Oct 10;7(19):5911-5924. doi: 10.1182/bloodadvances.2023010412.

本文引用的文献

1

Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.

J Cancer Res Clin Oncol. 2018 May;144(5):935-943. doi: 10.1007/s00432-018-2613-9. Epub 2018 Feb 21.

2

Late relapse of Hodgkin's lymphoma - is it different in clinical characteristics and outcome?

J BUON. 2017 Mar-Apr;22(2):481-486.

3

Prognostic factors in Hodgkin lymphoma.

Semin Hematol. 2016 Jul;53(3):155-64. doi: 10.1053/j.seminhematol.2016.05.003. Epub 2016 May 12.

4

Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.

J Clin Oncol. 2016 Jul 20;34(21):2493-500. doi: 10.1200/JCO.2015.65.4194. Epub 2016 Jun 6.

5

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.

6

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.

Adv Hematol. 2011;2011:707542. doi: 10.1155/2011/707542. Epub 2010 Dec 29.

7

Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study.

Leuk Lymphoma. 2010 Sep;51(9):1686-91. doi: 10.3109/10428194.2010.500432.

8

Very late relapse of Hodgkin's disease: a report of five patients.

Am J Clin Oncol. 2001 Dec;24(6):576-8. doi: 10.1097/00000421-200112000-00009.

9

Favorable prognosis after late relapse of Hodgkin's disease.

Cancer. 1998 Aug 1;83(3):560-5.

10

Late relapse after treatment for clinical stage I and II Hodgkin's disease.

Cancer. 1997 Apr 1;79(7):1422-7.